Radiomics and image-based artificial intelligence for predicting recurrence and survival after surgery in localised renal cell carcinoma: An APPRAISE-AI systematic review and meta-analysis
Comparison of patients with and without tumor pseudocapsule rupture during robot-assisted partial nephrectomy at a high-volume tertiary care referral center
LenCabo: A randomized phase II multicenter trial of lenvatinib plus everolimus (len/eve) versus (vs) cabozantinib (cabo) in patients (pts) with metastatic clear cell RCC (ccRCC) that progressed on PD-1 immune checkpoint inhibition (ICI)
First results from RAMPART: An international phase III randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL
Neoadjuvant immunotherapy in locally advanced clear cell renal cell carcinoma at risk for recurrence or distant metastases: The randomized phase II NESCIO trial
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial
Urine glycosaminoglycan scores for surveillance of recurrence in intermediate- and high-risk nonmetastatic clear cell renal cell carcinoma – An observational prospective multicentre diagnostic test cohort study
Exploratory analysis from NEOAVAX, a neoadjuvant trial of avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy
